Prognostic impact of FAS/CD95/APO-1 in urothelial cancers: decreased expression of Fas is associated with disease progression
暂无分享,去创建一个
K Takahashi | V. Bilim | Y. Tomita | N. Hara | Kota Takahashi | V Bilim | Y Tomita | T. Nishiyama | K. Yamana | T. Itoi | K Yamana | N Hara | T Kasahara | T Itoi | R Maruyama | T Nishiyama | R. Maruyama | T. Kasahara | K. Takahashi | Yoshihiko Tomita
[1] R. Hurst,et al. Bladder surface glycosaminoglycans: an epithelial permeability barrier. , 1990, The Journal of urology.
[2] J. Ro,et al. Cytologic and histologic features of superficial bladder cancer. , 1992, The Urologic clinics of North America.
[3] M. Weller,et al. Local Fas/APO‐1 (CD95) ligand‐mediated tumor cell killing in vivo , 1995, European journal of immunology.
[4] I. Herr,et al. Involvement of the CD95 (APO–1/Fas) receptor/ligand system in drug–induced apoptosis in leukemia cells , 1996, Nature Medicine.
[5] F. Shanahan,et al. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand , 1996, The Journal of experimental medicine.
[6] S. Nagata,et al. Apoptosis by Death Factor , 1997, Cell.
[7] M. Martínez-Lorenzo,et al. Doxorubicin‐induced apoptosis in human T‐cell leukemia is mediated by caspase‐3 activation in a Fas‐independent way , 1997, FEBS letters.
[8] Margot Thome,et al. Inhibition of death receptor signals by cellular FLIP , 1997, Nature.
[9] R. Greil,et al. Drug-induced apoptosis is associated with enhanced Fas (Apo-1/CD95) ligand expression but occurs independently of Fas (Apo-1/CD95) signaling in human T-acute lymphatic leukemia cells. , 1997, Cancer research.
[10] O. Yoshida,et al. Doxorubicin sensitizes human bladder carcinoma cells to Fas‐mediated cytotoxicity , 1997, Cancer.
[11] M. Parmar,et al. A randomized trial comparing methotrexate and vinblastine (MV) with cisplatin, methotrexate and vinblastine (CMV) in advanced transitional cell carcinoma: results and a report on prognostic factors in a Medical Research Council study. MRC Advanced Bladder Cancer Working Party. , 1998, British Journal of Cancer.
[12] D. Botstein,et al. Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer , 1998, Nature.
[13] Lawrence D. True,et al. The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder , 1998 .
[14] F. Mostofi,et al. The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee. , 1998, The American journal of surgical pathology.
[15] H. Stein,et al. ©1999 Cancer Research Campaign Article no. bjoc.1998.0202 , 2022 .
[16] M. Volm,et al. Expression of FAS (CD95/APO‐1) and FAS ligand in lung cancer, its prognostic and predictive relevance , 1999, International journal of cancer.
[17] W. Dalton,et al. Myeloma cells selected for resistance to CD95-mediated apoptosis are not cross-resistant to cytotoxic drugs: evidence for independent mechanisms of caspase activation. , 1999, Blood.
[18] Lee,et al. Transitional cell carcinoma expresses high levels of Fas ligand in vivo , 1999, BJU international.
[19] T. Kanematsu,et al. Frequency of apoptosis of tumor-infiltrating lymphocytes induced by fas counterattack in human colorectal carcinoma and its correlation with prognosis. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[20] P. Möller,et al. CD95 ligand (CD95L) immunohistochemistry: a critical study on 12 antibodies , 2001, Cell Death and Differentiation.
[21] M. Weller,et al. Soluble decoy receptor 3 is expressed by malignant gliomas and suppresses CD95 ligand-induced apoptosis and chemotaxis. , 2001, Cancer research.
[22] T. Shimada,et al. Preferential gene transfer to BBN-induced rat bladder tumor by simple instillation of adenoviral vector. , 2001, Urology.
[23] B. Hoel,et al. Doxorubicin Pretreatment Sensitizes Prostate Cancer Cell Lines to TRAIL Induced Apoptosis Which Correlates with the Loss of c-FLIP Expression , 2002, Cancer biology & therapy.
[24] V. Bilim,et al. Reverse transcription-polymerase chain reaction detection of prostate-specific antigen, prostate-specific membrane antigen, and prostate stem cell antigen in one milliliter of peripheral blood: value for the staging of prostate cancer. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[25] T. Eberlein,et al. Fas (CD95/APO‐1) and Fas ligand expression in normal pancreas and pancreatic tumors , 2002, Cancer.
[26] A. Lazaris,et al. Immunohistochemical study of pro-apoptotic factors Bax, Fas and CPP32 in urinary bladder cancer: prognostic implications , 2002, Urological Research.
[27] R. Herrmann,et al. DCR3 locus is a predictive marker for 5‐fluorouracil‐based adjuvant chemotherapy in colorectal cancer , 2002, International journal of cancer.
[28] L. Owen-Schaub,et al. Adenoviral Bid Overexpression Induces Caspase-dependent Cleavage of Truncated Bid and p53-independent Apoptosis in Human Non-small Cell Lung Cancers* , 2003, Journal of Biological Chemistry.
[29] V. Bilim,et al. Role of IRF-1 and caspase-7 in IFN-gamma enhancement of Fas-mediated apoptosis in ACHN renal cell carcinoma cells. , 2001, International journal of cancer.
[30] V. Bilim,et al. Role of XIAP in the malignant phenotype of transitional cell cancer (TCC) and therapeutic activity of XIAP antisense oligonucleotides against multidrug‐resistant TCC in vitro , 2003, International journal of cancer.
[31] V. Bilim,et al. Role of IRF‐1 and caspase‐7 in IFN‐γ enhancement of Fas‐mediated apoptosis in ACHN renal cell carcinoma cells , 2003 .
[32] D. Chopin,et al. Human urinary bladder transitional cell carcinomas acquire the functional Fas ligand during tumor progression. , 2003, The American journal of pathology.
[33] H. Kalthoff,et al. Resistance of pancreatic cancer to gemcitabine treatment is dependent on mitochondria‐mediated apoptosis , 2004, International journal of cancer.
[34] V. Bilim,et al. Adriamycin (ADM) induced apoptosis in Transitional Cell Cancer (TCC) cell lines accompanied by p21 WAF1/CIP1 induction , 2004, Apoptosis.
[35] A. Suminoe,et al. mRNA expression of apoptosis-associated genes in infant acute lymphoblastic leukemia: low Fas expression is an independent predictor for poor prognosis , 2004, Leukemia.
[36] W. Schulz,et al. Decreased Fas expression in advanced-stage bladder cancer is not related to p53 status. , 2004, Urology.
[37] V. Bilim,et al. Impact of frequent Bcl-2 expression on better prognosis in renal cell carcinoma patients , 2004, British Journal of Cancer.